Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2016, Article ID 9849328, 7 pages
http://dx.doi.org/10.1155/2016/9849328
Clinical Study

Comparison of the Effects of Continuous Subcutaneous Insulin Infusion and Add-On Therapy with Sitagliptin in Patients with Newly Diagnosed Type 2 Diabetes Mellitus

1Department of Endocrinology and Metabolism, The Third Affiliated Hospital of Southern Medical University, Guangzhou 510630, China
2School of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510515, China

Received 25 July 2015; Revised 21 September 2015; Accepted 28 September 2015

Academic Editor: Mitsuhiko Noda

Copyright © 2016 Heng Wan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. U.K. Prospective Diabetes Study Group, “U.K. Prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease,” Diabetes, vol. 44, no. 11, pp. 1249–1258, 1995. View at Publisher · View at Google Scholar
  2. W.-S. Lv, L. Li, J.-P. Wen et al., “Comparison of a multiple daily insulin injection regimen (glargine or detemir once daily plus prandial insulin aspart) and continuous subcutaneous insulin infusion (aspart) in short-term intensive insulin therapy for poorly controlled type 2 diabetes patients,” International Journal of Endocrinology, vol. 2013, Article ID 614242, 6 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. H. Yang, X. Heng, C. Liang et al., “Comparison of continuous subcutaneous insulin infusion and multiple daily insulin injections in Chinese patients with type 2 diabetes mellitus,” Journal of International Medical Research, vol. 42, no. 4, pp. 1002–1010, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. C. K. Kramer, B. Zinman, and R. Retnakaran, “Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis,” The Lancet Diabetes and Endocrinology, vol. 1, no. 1, pp. 28–34, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Weng, Y. Li, W. Xu et al., “Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial,” The Lancet, vol. 371, no. 9626, pp. 1753–1760, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. S. M. Pastores, “ACP Journal Club. Review: intensive insulin therapy does not reduce mortality but increases severe hypoglycemia in hospitalized patients,” Annals of Internal Medicine, vol. 155, no. 2, pp. C1–C12, 2011. View at Google Scholar · View at Scopus
  7. E. Nyenwe, “Intensive insulin therapy in hospitalised patients increases the risk of hypoglycaemia and has no effect on mortality, infection risk or length of stay,” Evidence-Based Medicine, vol. 17, no. 1, pp. 8–9, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. E. L. Johnson, “Glycemic variability in type 2 diabetes mellitus: oxidative stress and macrovascular complications,” Advances in Experimental Medicine and Biology, vol. 771, pp. 139–154, 2012. View at Google Scholar · View at Scopus
  9. M. Brownlee, “Biochemistry and molecular cell biology of diabetic complications,” Nature, vol. 414, no. 6865, pp. 813–820, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Brownlee, “The pathobiology of diabetic complications: a unifying mechanism,” Diabetes, vol. 54, no. 6, pp. 1615–1625, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Ceriello, K. Esposito, L. Piconi et al., “Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients,” Diabetes, vol. 57, no. 5, pp. 1349–1354, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. L. Piconi, L. Quagliaro, R. Assaloni et al., “Constant and intermittent high glucose enhances endothelial cell apoptosis through mitochondrial superoxide overproduction,” Diabetes/Metabolism Research and Reviews, vol. 22, no. 3, pp. 198–203, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Zhou, H. Li, X. Ran et al., “Reference values for continuous glucose monitoring in Chinese subjects,” Diabetes Care, vol. 32, no. 7, pp. 1188–1193, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Shen, Z. Chen, C. Chen, X. Zhu, and Y. Han, “Impact of incretin on early-phase insulin secretion and glucose excursion,” Endocrine, vol. 44, no. 2, pp. 403–410, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Zhao, L. Yang, and Z. Zhou, “Dipeptidyl peptidase-4 inhibitors: multitarget drugs, not only antidiabetes drugs,” Journal of Diabetes, vol. 6, no. 1, pp. 21–29, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. D. M. Riche, H. E. East, and K. D. Riche, “Impact of sitagliptin on markers of β-cell function: a meta-analysis,” American Journal of the Medical Sciences, vol. 337, no. 5, pp. 321–328, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Nalysnyk, M. Hernandez-Medina, and G. Krishnarajah, “Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature,” Diabetes, Obesity & Metabolism, vol. 12, no. 4, pp. 288–298, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. M. R. Rizzo, M. Barbieri, R. Marfella, and G. Paolisso, “Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition,” Diabetes Care, vol. 35, no. 10, pp. 2076–2082, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Katsuno, H. Ikeda, K. Ida, J.-I. Miyagawa, and M. Namba, “Add-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus,” Endocrine Journal, vol. 60, no. 6, pp. 733–742, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. E. S. Hong, A. R. Khang, J. W. Yoon et al., “Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study,” Diabetes, Obesity & Metabolism, vol. 14, no. 9, pp. 795–802, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. T. Vilsbøll, J. Rosenstock, H. Yki-Järvinen et al., “Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes,” Diabetes, Obesity & Metabolism, vol. 12, no. 2, pp. 167–177, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. G. Yuan, J. Jia, C. Zhang et al., “Safety and efficacy of sitagliptin in combination with transient continuous subcutaneous insulin infusion (CSII) therapy in patients with newly diagnosed type 2 diabetes,” Endocrine Journal, vol. 61, no. 5, pp. 513–521, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. G. Yuan, H. Hu, S. Wang et al., “Improvement of β-cell function ameliorated glycemic variability in patients with newly diagnosed type 2 diabetes after short-term continuous subcutaneous insulin infusion or in combination with sitagliptin treatment: a randomized control trial,” Endocrine Journal, vol. 62, no. 9, pp. 817–834, 2015. View at Publisher · View at Google Scholar
  24. K. J. Hare, T. Vilsbøll, M. Asmar, C. F. Deacon, F. K. Knop, and J. J. Holst, “The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action,” Diabetes, vol. 59, no. 7, pp. 1765–1770, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Yoshiuchi, M. Matsuhisa, N. Katakami et al., “Glycated albumin is a better indicator for glucose excursion than glycated hemoglobin in type 1 and type 2 diabetes,” Endocrine Journal, vol. 55, no. 3, pp. 503–507, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Xu, C. D. Man, B. Charbonnel et al., “Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach,” Diabetes, Obesity & Metabolism, vol. 10, no. 12, pp. 1212–1220, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Karasik, P. Aschner, H. Katzeff, M. J. Davies, and P. P. Stein, “Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials,” Current Medical Research and Opinion, vol. 24, no. 2, pp. 489–496, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. R. C. Turner, H. Millns, H. A. W. Neil et al., “Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: united Kingdom prospective diabetes study (UKPDS: 23),” British Medical Journal, vol. 316, no. 7134, pp. 823–828, 1998. View at Publisher · View at Google Scholar · View at Scopus
  29. A. J. Tremblay, B. Lamarche, C. F. Deacon, S. J. Weisnagel, and P. Couture, “Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes,” Diabetes, Obesity & Metabolism, vol. 13, no. 4, pp. 366–373, 2011. View at Publisher · View at Google Scholar · View at Scopus